Articles

The practicality and expense of maintaining patients on total artificial hearts (TAH) may be significantly impacted with the introduction of a new, investigational portable driver unit. The 13-...

New U.S. Food and Drug Administration (FDA) indications for two key heart failure device therapies may help improve survival, slow the progress of the disease and, in some cases, reverse its...

The intra-aortic balloon pumps (IABPs) have been the gold standard for minimally invasive circulatory support for 40 years, but they were joined in recent years by percutaneously deployed...

Intra-aortic balloon pumps (IABPs), introduced in the 1970s, have been considered the standard of care for short-term circulatory support for more than two decades. However, there has been a...

A 55-year-old woman with a history of heavy alcohol use, hepatitis C induced cirrhosis, hypertension, and chronic renal insufficiency presented at Massachusetts General Hospital in Boston Mass.,...

There is growing interest in going beyond using ventricular assist devices (VADs) just for end-stage heart failure and expanding use for therapeutic recovery in patients with cardiogenic shock,...

When it comes to treating patients suffering from heart failure, which is typically defined as a heart whose pumping power is weaker than normal, physicians are facing a paradox.